Sensydia Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Sensydia Corporation's estimated annual revenue is currently $256k per year.
- Sensydia Corporation's estimated revenue per employee is $32,000
Employee Data
- Sensydia Corporation has 8 Employees.
- Sensydia Corporation grew their employee count by -33% last year.
Sensydia Corporation's People
Name | Title | Email/Phone |
---|---|---|
1 | CMO | Reveal Email/Phone |
2 | Software Engineer | Reveal Email/Phone |
3 | Product Development Engineer | Reveal Email/Phone |
Sensydia Corporation Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $8.2M | 27 | 80% | N/A | N/A |
#2 | $0.3M | 8 | -33% | N/A | N/A |
#3 | $1.7M | 68 | 106% | N/A | N/A |
#4 | $4M | 24 | 14% | $26.1M | N/A |
#5 | $1.7M | 4 | 0% | $1.7M | N/A |
#6 | $7.5M | 29 | 21% | N/A | N/A |
#7 | $3.5M | 15 | 0% | $37.9M | N/A |
#8 | $1.1M | 14 | 133% | N/A | N/A |
#9 | $1.1M | 6 | 50% | N/A | N/A |
#10 | $3.4M | 20 | -5% | N/A | N/A |
What Is Sensydia Corporation?
Sensydia is developing a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.
keywords:N/AN/A
Total Funding
8
Number of Employees
$256k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.6M | 8 | N/A | N/A |
#2 | $0.8M | 8 | N/A | N/A |
#3 | $0.6M | 8 | N/A | N/A |
#4 | $0.5M | 8 | N/A | N/A |
#5 | $0.6M | 8 | N/A | N/A |